SRXH
SRx Health Solutions Inc.0.3769
+0.0724+23.8%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.45MP/E (TTM)
-Basic EPS (TTM)
-0.41Dividend Yield
0%Recent Filings
8-K
Secures $4.5M via preferred
SRx Health Solutions closed a private placement on March 16, 2026, issuing 5,660 Series B preferred shares and warrants for 22.2M common shares, netting $4.5M cash. Up to $3.5M more follows at investor option. Preferred ranks senior to common, converts at $0.3182, but dilution covenants bind until stockholder nod. Cash bolsters runway, yet warrants loom large.
8-K
Waivers enable Series B offering
SRx Health Solutions secured waivers from existing note and Series A preferred investors on March 2, 2026, clearing the path for a new Series B preferred stock offering. Holders waived participation rights and consented to Series B ranking pari passu with Series A on dividends and liquidation. Waivers are one-time only. Path now open for fresh capital.
8-K
NYSE warning for listing violations
SRx Health Solutions received a public NYSE warning letter on February 18, 2026, for violating listing rules by issuing ~7.5 million common shares upon Series A preferred conversion without prior exchange approval or adequate shareholder consent. All preferred shares are now converted or redeemed. Future non-compliance risks delisting proceedings.
10-Q
Q1 FY2026 results
SRx Health Solutions posted $2.8M net sales for Q1 FY2026 ended December 31, 2025 from its Halo pet products—92% digital—versus zero prior year as prior ops were discontinued (y/y derived). Gross profit hit 38% yet operating loss reached $3.8M on $4.8M SG&A, while net loss widened to $8.6M ($0.26/share) from $3.1M debt extinguishment and $1.3M interest versus operating loss alone. Cash swelled to $13.1M via $23.1M financing (ELOC, preferred stock), funding $8.5M digital assets buy; $21M short-term convertible debt (5% ELOC note) looms. Cash burn hit $2.9M; no FCF as capex zero. Digital channel dominates. Crypto volatility threatens holdings.
8-K
Redeems preferred stock, cancels 125M shares
SRx Health Solutions redeemed all 17,418 shares of its Series A Convertible Preferred Stock on February 11, 2026, for ~$21.8M, canceling ~125M common shares on an as-converted basis. Issued in October 2025 for $15.23M proceeds, the redemption cleans up the balance sheet. Flexibility now targets future M&A or capital returns. No immediate deals planned.
CPMD
Cannapharmarx Inc.
0.00-0.00
EHC
Encompass Health Corporation
108.01+0.42
FCHS
First Choice Healthcare Solutio
0.01+0.00
GRDN
Guardian Pharmacy Services, Inc
30.64+0.20
MCK
McKesson Corporation
809.96-13.05
NUTX
Nutex Health Inc.
171.72-4.06
PIII
P3 Health Partners Inc.
4.59-0.36
PMHS
Polomar Health Services, Inc.
0.08+0.00
SYRA
Syra Health Corp.
0.07+0.01
UHS
Universal Health Services, Inc.
222.64-1.23